Skip to main content
MyDeficiencies

Cariprazine

atypical (third-generation) antipsychotic, D3-preferring partial agonist

Also sold as Vraylar.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Cariprazine has almost none of the classical drug-nutrient depletion machinery this series screens for, but it has an unusually complicated pharmacokinetic identity that shapes everything else in this dossier. It is extensively metabolized, mainly by CYP3A4 and to a lesser extent CYP2D6, into two active metabolites: desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR). DDCAR has an elimination half-life of roughly one to three weeks and does not approach steady state until week four to week eight of dosing; by week 12 it circulates at roughly four times the concentration of the parent drug. Practically, this means cariprazine's effects, and any adverse signal attributed to it, can build for two months after a dose change and persist for weeks after the drug is stopped, unlike shorter-acting antipsychotics in this series. The label documents no clinically meaningful food effect on absorption, no chelation or gastric-pH-dependent absorption mechanism, no renal wasting of electrolytes or minerals, and only about 1.2 percent of a dose excreted in urine as unchanged drug. Cariprazine is not itself a clinically significant inducer of the hepatic enzymes that catabolize vitamins; the label does not even know the net effect of CYP3A4 inducers on cariprazine's own levels and simply advises against combining them. On pharmacokinetics alone, this is a drug with low prior plausibility for classical nutrient depletion, similar to the other second- and third-generation antipsychotics already reviewed in this series.

atypical (third-generation) antipsychotic, D3-preferring partial agonist · ATC N05AX15 · also sold as Vraylar · reviewed 2026-09-30. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Cariprazine in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, in vitro and ex vivo evidence at supratherapeutic concentrations only

Yellow — Low

See study details

Three independent drug-specific in vitro/ex vivo studies find cariprazine inhibits mitochondrial electron transport chain activity, but only at concentrations roughly 25 to several hundred times above typical patient serum levels; no human clinical mitochondrial-marker study in cariprazine-treated patients was located.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null/negative findings: Hardy et al. found no effect in primary forebrain neurons even though ventral midbrain neurons showed an ATP reduction, indicating the effect is not uniform across neuronal populations. No in vivo human study at therapeutic dosing was located to confirm or refute a clinical-dose effect.
  • At-risk subgroups: Not established in humans; theoretical only, and the authors of the Biology Direct paper frame their concern around long-term extrapyramidal and post-discontinuation neurological effects, not a general fatigue or energy complaint.

Regulatory status

Not addressed in the FDA label.

Population evidence

Hardy et al., Biology Direct 2023 (PMID 37528429, DOI 10.1186/s13062-023-00375-9; bovine/mouse isolated mitochondria, human SH-SY5Y neuroblastoma cells, primary mouse forebrain and ventral midbrain neurons, and live Drosophila melanogaster ): cariprazine, alongside aripiprazole and brexpiprazole, produced a significant decline in pyruvate/malate-driven (complex I-dependent) respiration at 5 to 10 micromolar after a 2-hour preincubation, with dose-dependent reductions in NADH oxidation specific to the ubiquinone-binding (Q) site; patient serum levels are reported in the same paper as 0.09 to 0.4 micromolar for cariprazine, roughly 25 to over 100-fold below the tested concentration. Ľupták, Fišar and Hroudová, Molecular Neurobiology 2021 (DOI 10.1007/s12035-021-02498-4; isolated pig brain mitochondria, in vitro): cariprazine, brexpiprazole, loxapine, and lurasidone all significantly decreased electron transport chain activity and ATP production at higher concentrations, with the effect appearing at 100 micromolar for cariprazine specifically. Mitrovic et al., Biomedicines 2026 (DOI 10.3390/biomedicines14020315; HeLa and HCT116 human cancer cell lines, in vitro): cariprazine produced concentration-dependent cytotoxicity (IC50 approximately 30 micromolar) with molecular docking predicting stable binding at the Qi site of cytochrome bc1 (complex III), comparable to the classic complex III inhibitor antimycin A; this is explicitly exploratory anticancer research in cancer cell lines, not a toxicology or psychiatric-dosing study.

Mechanism

Direct off-target inhibition of electron transport chain complex I (Hardy 2023) and, separately proposed, complex III at the Qi site (Mitrovic 2026), plus broader electron-transport-chain and ATP-synthesis disruption (Ľupták 2021), all requiring concentrations well above typical clinical plasma exposure.

Counter-evidence held on record

All three concentrations tested (5 to 10, 30, and 100 micromolar) are well above the 0.09 to 0.4 micromolar range reported for cariprazine in patient serum. This entry shares its primary sources with ATP production and, for the Ľupták study, with oxidative stress; see Overlap map, not three independent confirmations. Do not interpret this entry as support for mitochondrial-support supplementation such as coenzyme Q10 in patients on cariprazine; no clinical trial evidence supports this, and the coenzyme Q10 claim fails verification separately below.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, single in vitro dataset, no human data located

Yellow — Low

See study details

The only direct oxidative-stress data for cariprazine come from the same isolated pig-brain-mitochondria study cited under mitochondrial burden, which found a dose-dependent rise in hydrogen peroxide at the highest concentration tested; no human, in vivo, or antioxidant-marker study in cariprazine-treated patients was located.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null/negative findings: A direct PubMed search for "cariprazine oxidative stress" returned three results, none of which was a human, in vivo, or drug-specific oxidative-stress biomarker study in cariprazine-treated patients; two were general reviews (one on ketamine/neuromodulation, one on bipolar disorder and mitochondrial dysfunction broadly) and one was an unrelated analytical chemistry degradation study. No human null or positive finding for cariprazine specifically was located in either direction.
  • At-risk subgroups: Not established; theoretical only.

Regulatory status

Not addressed in the FDA label.

Population evidence

Ľupták, Fišar and Hroudová, Molecular Neurobiology 2021 (DOI 10.1007/s12035-021-02498-4, isolated pig brain mitochondria, in vitro): hydrogen peroxide production increased significantly at 100 micromolar cariprazine (and loxapine), a threshold ten times higher than the 10 micromolar at which brexpiprazole and lurasidone showed the same effect in the same experiment, suggesting cariprazine's pro-oxidant signal is comparatively weaker within this small drug set. The same paper found cariprazine acted as a partial monoamine oxidase-A inhibitor, a separate redox-adjacent finding not independently verified elsewhere for cariprazine.

Mechanism

Proposed as a downstream consequence of electron-transport-chain disruption at supratherapeutic concentrations (shared source and mechanism with Mitochondrial burden and ATP production above; see Overlap map). No named antioxidant-capacity or lipid-peroxidation mechanism specific to cariprazine at clinical concentrations was located.

Counter-evidence held on record

Unlike risperidone, cariprazine does not meaningfully raise prolactin (see Fails verification below), so the hyperprolactinemia-linked antioxidant/pro-oxidant literature described for other antipsychotics in this series does not carry over to cariprazine by that route; no separate human redox dataset for cariprazine exists to confirm or contradict the in vitro pro-oxidant direction. This is a single supratherapeutic in vitro finding and does not support antioxidant supplementation in patients on cariprazine.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron, class-level extrapolation via antipsychotic-induced akathisia, not cariprazine-specific data

Yellow — Low

See study details

A class-level meta-analysis links lower iron and ferritin to antipsychotic-induced akathisia, but every included study predates cariprazine's 2015 approval; cariprazine itself carries one of the highest labeled akathisia incidences of any current antipsychotic, which is real drug-specific evidence for the adverse reaction but not for an iron effect.

Full detail, limits and 1 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null/negative findings: The same meta-analysis reports a weaker and less consistent signal for ferritin than for serum iron, and the studies were cross-sectional, so reverse causation (akathisia-related reduced food intake lowering iron) cannot be excluded. No study measuring iron status specifically in cariprazine-treated patients, positive or null, was located.
  • At-risk subgroups: Not established for cariprazine specifically; by class-level analogy, patients with baseline low-normal iron or ferritin starting a high-akathisia-liability antipsychotic.

Regulatory status

The FDA label does not mention iron, ferritin, or any hematologic mineral study; akathisia and extrapyramidal symptoms are labeled adverse reactions with dose-response percentages (see Pharmacokinetic basis and Monitoring panel).

Population evidence

Schoretsanitis, Nikolakopoulou, Guinart, Correll and Kane, European Neuropsychopharmacology 2020 (DOI 10.1016/j.euroneuro.2020.04.001): systematic review and meta-analysis of 10 cross-sectional studies (n=395; 182 with akathisia, 213 without) found serum iron significantly lower in patients with akathisia (SMD -0.49, 95% CI -0.70 to -0.28, p<0.001, fixed-effect model); ferritin showed a weaker, fixed-effect-only signal. The named individual studies identified in this review (Brown 1987, Barton 1990, Hofmann 2000, Kuloglu 2003, and others) were published years before cariprazine's approval and studied first-generation and early second-generation antipsychotics, not cariprazine. Separately, cariprazine's own FDA label and pivotal trials report akathisia in 9 to 14 percent of schizophrenia patients and 20 to 21 percent of bipolar mania patients (versus 4 to 5 percent placebo), among the higher rates in its drug class; this is drug-specific Tier A evidence for the akathisia adverse reaction itself, not for an iron mechanism.

Mechanism

The proposed mechanism (from the older, non-cariprazine literature) is that low brain iron impairs striatal dopamine D2 receptor function, lowering the threshold for extrapyramidal symptoms including akathisia; cariprazine's own pharmacology (partial D2/D3 agonism with high D3 affinity) is mechanistically distinct from the full D2 antagonists studied in the iron literature, so the extrapolation is plausible but not confirmed for a partial-agonist mechanism.

Counter-evidence held on record

Under Hard Rule 6, confounding by indication and by class-drug substitution is presumed until excluded, and it is not excluded here: no cariprazine patient was in the iron/ferritin-measured cohort. Cariprazine's own akathisia incidence (this entry's only drug-specific fact) is a clinical outcome, not a nutrient measurement, and is cited here as context per Hard Rule 2, not as iron evidence; see Overlap map. Do not supplement iron in a cariprazine-treated patient based on akathisia symptoms alone. Iron overload carries its own toxicity risk; any repletion should follow a lab-confirmed low ferritin or iron panel and be prescriber-directed, kept under the NIH Office of Dietary Supplements tolerable upper intake level for elemental iron (45 mg/day for adults). This dossier makes no standing dosing recommendation.

Copper, weak class extrapolation from typical antipsychotics only; cariprazine and its D2/D3 partial-agonist class absent from the drug-specific literature

Yellow — Low

See study details

A large meta-analysis found elevated plasma copper in schizophrenia patients treated with typical (first-generation, full D2-antagonist) antipsychotics, but no study naming cariprazine, or any D2/D3 partial agonist, in connection with copper was located; the class member with real data is pharmacologically distant from cariprazine, so this is graded yellow on weak extrapolation only.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null/negative findings: This session's direct searches for "cariprazine copper" (PubMed, zero results) and for aripiprazole- or brexpiprazole-specific copper data (Crossref and PubMed, no drug-specific results returned among any of the antipsychotic-and-copper records retrieved) found no evidence at any tier connecting a D2/D3 partial agonist to copper status. The Saghazadeh meta-analysis's own restriction of its positive finding to "typical antipsychotic drugs" is itself a form of negative evidence against extending the finding to atypical or partial-agonist drugs without further data.
  • At-risk subgroups: Not established for cariprazine or any D2/D3 partial agonist. By weak class analogy only, patients on long-term typical/first-generation antipsychotics, a different drug class than cariprazine.

Regulatory status

Copper is not mentioned anywhere in the FDA label (searched directly against the full prescribing information text for "copper," "ceruloplasmin," and related terms during this review; none appear).

Population evidence

Saghazadeh, Mahmoudi, Meysamie, et al., Nutrition Reviews 2020 (DOI 10.1093/nutrit/nuz059; systematic review and meta-analysis of 39 studies, n=5,151): found schizophrenia patients overall had higher plasma copper, lower iron, and lower zinc than healthy controls, and specifically reported "higher levels of copper in plasma, in users of typical antipsychotic drugs, and in males" (quoted directly from the abstract). The abstract ties the copper elevation to typical, not atypical or partial-agonist, antipsychotic use; full text was not accessible (no open-access location via Unpaywall, publisher page blocked by robots.txt), so whether atypical antipsychotics were separately tested and found null, or simply not broken out, could not be confirmed. Herrán, Vázquez-Barquero, González-Hoyos, et al., Psychiatry Research 2000 (DOI 10.1016/S0165-1781(00)00126-8), titled "Higher levels of serum copper in schizophrenic patients treated with depot neuroleptics," is consistent in direction with the Saghazadeh meta-analysis; only the title and bibliographic record were accessible this session, not the full abstract, so it is cited as corroborating, title-confirmed context rather than a fully independent verified source.

Mechanism

No mechanism specific to copper and antipsychotic treatment was stated in the accessible abstract. Ceruloplasmin, the major plasma copper-carrier protein, is a positive acute-phase reactant, which is one plausible general explanation for elevated plasma copper in an inflammatory or stress state, but this was not confirmed as the mechanism in either cited source and is noted here only as background plausibility, not as a sourced claim. No mechanism connecting D2/D3 partial agonism specifically (as opposed to full D2 antagonism) to copper handling was located.

Counter-evidence held on record

The positive finding underlying this entry is specific to typical antipsychotics, a full D2-antagonist class pharmacologically distinct from cariprazine's D3-preferring partial agonism, and cariprazine was not in the meta-analysis's cohort. This is a materially weaker extrapolation than most class-level yellow entries in this series, where at least a related atypical or same-mechanism-class drug carried the positive data. Do not supplement or restrict copper in a cariprazine-treated patient based on this entry. Copper is both essential and toxic in excess; the NIH Office of Dietary Supplements tolerable upper intake level for adults is 10,000 mcg (10 mg)/day. This dossier makes no standing dosing recommendation.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, weak class extrapolation only; cariprazine absent from the drug-specific literature

Yellow — Low

See study details

A 2026 drug-specific review of antipsychotic-associated gut microbiome remodeling does not mention cariprazine at all; any concern here rests on mechanistic analogy to aripiprazole, a related D2/D3 partial agonist with "emerging" but limited microbiome data, and is undercut by cariprazine's own comparatively favorable weight and metabolic profile.

Full detail, limits and 3 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null/negative findings: No cariprazine-specific microbiome study, positive or null, was located. The absence of cariprazine from a comprehensive, recent, drug-specific review is itself informative and is treated here as a negative finding for the strength of any drug-specific claim, not as proof of no effect.
  • At-risk subgroups: Not established for cariprazine; by weak class analogy, patients with substantial cariprazine-associated weight gain, though this is a minority per the EHR cohort above.

Regulatory status

Not addressed in the FDA label.

Population evidence

A 2026 review, "Antipsychotic-Induced Remodeling of the Gut Microbiota: Drug-Specific Patterns and Molecular Links to Metabolic Adverse Effects" ( Int J Mol Sci, DOI-indexed on MDPI), surveys olanzapine (most-studied), risperidone (second most-studied), clozapine, quetiapine, aripiprazole ("emerging data"), lurasidone, and amisulpride; a full-text search for "cariprazine" in that review returns no results. Contrasting drug-specific metabolic data for cariprazine itself: Masand et al., Clinical Therapeutics 2024 (DOI 10.1016/j.clinthera.2023.10.015; retrospective EHR cohort, n=2,301 for the primary weight analysis): most cariprazine-treated patients experienced neither clinically significant weight gain (82.8 percent below the 7 percent threshold) nor weight loss (90.5 percent below threshold), with favorable trends in HbA1c and triglyceride trajectories relative to the pre-treatment baseline. Verma et al., J Psychiatr Res 2026 (DOI 10.1016/j.jpsychires.2026.02.037; 12-week RCT, n=98, patients switched from olanzapine due to weight gain): cariprazine produced modestly greater weight reduction than aripiprazole (mean difference 0.82 kg), with both arms improving cardiometabolically.

Mechanism

The weight-gain-associated microbiome remodeling documented for olanzapine and risperidone is mechanistically tied to those drugs' own metabolic-syndrome liability (Hard Rule 2 territory: an outcome, not a direct microbiome measurement, in most of that literature). Cariprazine's D3-preferring partial agonism gives it a different, generally more weight-neutral receptor profile than full D2 antagonists, which is the basis for grading this only yellow (plausible by class analogy) rather than orange or higher.

Counter-evidence held on record

Cariprazine's own metabolic data (EHR cohort and head-to-head RCT against aripiprazole) point toward a comparatively favorable, near weight-neutral profile, which argues against, not for, the magnitude of microbiome disruption documented for olanzapine and risperidone applying to cariprazine with similar force. This entry shares its metabolic-profile evidence with the headline finding; see Overlap map. No probiotic strain or dose has clinical trial support for cariprazine-treated patients. Do not substitute probiotic supplementation for standard metabolic monitoring (weight, glucose, lipids).

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production, same supratherapeutic in vitro/ex vivo datasets as mitochondrial burden

Yellow — Low

See study details

The same two drug-specific mechanistic studies that show electron transport chain inhibition also show reduced ATP output, again only at concentrations far above therapeutic exposure; no in vivo or clinical energy-metabolism marker study in cariprazine-treated patients was located.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow

Limits on what this shows

  • Null/negative findings: No ATP reduction in primary forebrain neurons in the Hardy et al. preparation, despite a clear effect in ventral midbrain neurons from the same study. No in vivo human clinical energy-metabolism study was located.
  • At-risk subgroups: Not established; the findings come from toxicological/mechanistic exposure ranges, not chronic therapeutic dosing in patients.

Regulatory status

Not addressed in the FDA label.

Population evidence

Ľupták, Fišar and Hroudová, Molecular Neurobiology 2021 (DOI 10.1007/s12035-021-02498-4, isolated pig brain mitochondria): "all tested antipsychotics decreased mitochondrial ATP production" at higher concentrations, cariprazine included. Hardy et al., Biology Direct 2023 (PMID 37528429, primary mouse ventral midbrain neurons): approximately 20 percent ATP reduction after cariprazine exposure, with no effect in primary forebrain neurons from the same preparation.

Mechanism

Proposed as a direct downstream consequence of electron transport chain (complex I and, per the separate Mitrovic 2026 cancer-cell study, possibly complex III) inhibition at supratherapeutic concentrations. This entry shares both of its primary sources with Mitochondrial burden above; see Overlap map, not counted as independent confirmation.

Counter-evidence held on record

No clinical correlate, such as fatigue, exercise capacity, or lactate, has been studied in cariprazine-treated patients specifically. Region-specificity (midbrain affected, forebrain not) in the one study that tested multiple neuronal populations argues against a uniform, whole-body ATP effect even within the animal model. Does not support ATP-support supplementation, such as coenzyme Q10 or creatine, in patients on standard therapeutic cariprazine dosing.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No cariprazine-specific or dopamine-partial-agonist-class evidence on hemoglobin, hematocrit, anemia, or tissue oxygen delivery was located at any tier, and no circulating consumer claim naming cariprazine and oxygen-carrying capacity was located to rebut.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Both conditions for ungraded status are met: no Tier B or Tier C evidence supports even a yellow grade for cariprazine specifically or for its D2/D3 partial-agonist class, and no circulating claim was located naming cariprazine and anemia, hemoglobin, or oxygen delivery together for this review to rebut as white.

Channels tried

PubMed search-listing pages, multiple phrasings ("cariprazine anemia": zero results, confirmed on a repeat attempt in this revision pass; "cariprazine hemoglobin": 2 results, both about weight/metabolic parameters and an umbrella review of physical-health interventions in mood disorders, neither a hemoglobin- or oxygen-delivery-specific finding). FDA label: searched directly against the full prescribing information text this revision pass for "copper," "ceruloplasmin," "anemia," "hemoglobin," "hematocrit," "red blood cell," and "oxygen": none appear; the label's only hematologic content is the leukopenia/neutropenia/agranulocytosis warning (white-cell, immune-mediated, requiring CBC monitoring), which is a white-cell not a red-cell or oxygen-delivery finding and is not filed here, consistent with the same logic this series applied to risperidone's white-cell case reports. Crossref API, this revision pass: "aripiprazole brexpiprazole hemoglobin anemia" (13 results, all pharmacology/efficacy/adverse-psychiatric-effect literature, none hematologic) and "antipsychotic hemoglobin anemia schizophrenia" (15 results, none studying hemoglobin/anemia as a treatment outcome) both returned working result sets with no relevant hit, a genuine negative rather than a blocked attempt. Europe PMC REST API and NCBI eutils: confirmed blocked at the session's network layer by organization-level proxy policy (HTTP 403, "gateway answered 403 to CONNECT"), verified directly against the proxy status endpoint this revision pass, which logged repeated policy-level connection rejections for eutils.ncbi.nlm.nih.gov, www.ebi.ac.uk, api.crossref.org, api.openalex.org, api.semanticscholar.org, dailymed.nlm.nih.gov, www.accessdata.fda.gov, and api.unpaywall.org at the raw-connection level, even though the WebFetch tool itself (a separate fetch path) was able to reach PubMed, Crossref, and the FDA label directly for part of this session before PubMed began returning reCAPTCHA pages and Semantic Scholar/OpenAlex began returning HTTP 429/503 to WebFetch as well. Unpaywall: reachable via WebFetch for one lookup (confirmed no open-access copy of the Saghazadeh copper meta-analysis), then not re-tried for this category.

Outcome

No case report, cohort study, or class-level source linking cariprazine, or any D2/D3 partial-agonist antipsychotic, to anemia, hemoglobin change, hematocrit, or impaired oxygen delivery was found this revision pass. This differs from risperidone, where at least a single case report existed to grade yellow; for cariprazine, even that thin a signal was not located, and the partial-agonist class specifically (aripiprazole, brexpiprazole) also returned nothing on a direct check.

Genuine gap vs tooling limited

Assessed as substantially a genuine evidence gap, more so after this revision pass than before it. The PubMed, Crossref, and FDA-label channels that did return results this session returned working, on-topic result sets with no hematologic or oxygen-delivery hit for cariprazine or its pharmacological class, which is a real (if not exhaustive) negative rather than a blocked attempt. This is still compounded by a genuine, confirmed tooling limitation: Europe PMC and NCBI eutils were never reachable at the raw-connection level this session (a hard proxy policy denial, not a rate limit expected to lift with time), and PubMed, Semantic Scholar, and OpenAlex became rate-limited or bot-gated partway through the review, preventing an exhaustive set of phrasings from being tried against every channel. A future revision should re-attempt the blocked and rate-limited channels, ideally from a session where those specific hosts are not policy-denied, before treating this gap as fully closed.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Calcium and vitamin D supplementation corrects cariprazine-associated bone density loss

    Where it comes from: A reasonable-seeming inference carried over from other antipsychotics' hyperprolactinemia-associated bone density reduction (documented elsewhere in this series for risperidone), combined with the general "low bone density means take calcium and vitamin D" framing common in consumer nutrition content, and applied to cariprazine by class assumption.

    Why it fails: A Tier A pooled post hoc analysis across acute and long-term schizophrenia, bipolar mania, and bipolar depression trials (Culpepper, Vieta, Kelly, Patel, Szatmári, Hankinson and Earley, Neuropsychiatric Disease and Treatment 2022, DOI 10.2147/NDT.S348143; over 3,000 patients pooled) found cariprazine's median prolactin changes were minimal and "similar to what was seen in the placebo and aripiprazole groups," in contrast to risperidone, which produced marked increases in the same comparison. Without the hyperprolactinemia mechanism, the entire premise for a bone-density-driven calcium/vitamin D claim does not apply to cariprazine specifically, so recommending calcium and vitamin D on this basis is not evidence-based for this drug.

  • Cariprazine (or antipsychotics generally) depletes coenzyme Q10

    Where it comes from: Circulates in general antipsychotic and psychiatric-medication drug-nutrient depletion handbook-style content (Tier D, no drug-specific citation), part of a broader genre applying mitochondrial-support nutrient claims across psychiatric medications; one such source reviewed for this dossier names aripiprazole, quetiapine, and risperidone specifically but not cariprazine.

    Why it fails: A PubMed search for "cariprazine oxidative stress" (the closest available proxy, since a direct "cariprazine coenzyme Q10" search was not separately run before the session's search channels became rate-limited) returned no drug-specific human CoQ10 or mitochondrial-marker study, only two unrelated reviews and one analytical chemistry paper. No Tier B or Tier C evidence exists connecting cariprazine specifically, or D3-preferring partial agonists as a class, to coenzyme Q10 status, and this drug-nutrient pairing could not be traced to any primary source.

How the body handles this medication

Metabolism
Extensively metabolized, mainly by CYP3A4 and to a lesser extent CYP2D6, forming two major active metabolites: desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR). DCAR is further metabolized to DDCAR by CYP3A4 and CYP2D6; DDCAR is then hydroxylated by CYP3A4.FDA label / DailyMed SPL, Clinical Pharmacology 12.3
Active-metabolite half-life and accumulation
Cariprazine half-life 2 to 4 days; DCAR 1 to 2 days; DDCAR approximately 1 to 3 weeks, approaching steady state only around week 4 to week 8. By week 12, mean DCAR concentration is about 30 percent and DDCAR about 400 percent of cariprazine's own concentration. This long tail is the drug's single most distinctive pharmacokinetic feature and means effects can build or persist for weeks around a dose change or discontinuation.FDA label / DailyMed SPL, Clinical Pharmacology 12.3
CYP450 induction/inhibition
The label does not identify cariprazine itself as a clinically significant inducer or inhibitor of CYP450 enzymes; in vitro data suggest low risk of cariprazine altering CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E, or 3A4 substrates. Cariprazine is a CYP3A4 (major) and CYP2D6 (minor) substrate: the strong inhibitor ketoconazole raised total cariprazine Cmax/AUC by about 100 percent (a 5.5 to 6-fold increase predicted at steady state); the moderate inhibitor erythromycin raised it about 50 percent. The effect of CYP3A4 inducers "has not been evaluated, and the net effect is unclear"; concomitant use with a CYP3A4 inducer is "not recommended."FDA label / DailyMed SPL, sections 2.6 and 12.3
Elimination
About 21 percent of a daily dose is recovered in urine, but only about 1.2 percent as unchanged cariprazine; the drug is extensively metabolized before excretion rather than cleared renally unchanged. Cariprazine and its metabolites are highly protein-bound (91 to 97 percent).FDA label / DailyMed SPL
Absorption
Peak plasma cariprazine concentration at approximately 3 to 6 hours after a single dose. A high-fat meal did not significantly affect the Cmax or AUC of cariprazine or DCAR; no clinically meaningful food effect, chelation, gastric-pH, or transporter-mediated absorption mechanism is described.FDA label / DailyMed SPL, Clinical Pharmacology 12.3
Renal and hepatic impairment
No dosage adjustment for mild to moderate hepatic impairment or mild to moderate renal impairment (CrCl 30 mL/min or greater). For severe hepatic impairment or severe renal impairment (CrCl under 30 mL/min), "usage of VRAYLAR is not recommended" outright, rather than a lower maintenance dose, reflecting concern about metabolite accumulation on top of an already long half-life.FDA label / DailyMed SPL
All references used above
  1. VRAYLAR (cariprazine) capsules, prescribing information. — FDA-approved label via accessdata.fda.gov, 2024 revision (204370s012lbl.pdf), cross-checked against DailyMed SPL (Allergan, Inc., setid 4b5f7c65-aa2d-452a-b3db-bc85c06ff12f, effective December 18, 2025). Used for Clinical Pharmacology (12.3), dosing (2.6), adverse reaction tables (6.1), and impairment guidance.
  2. DailyMed - VRAYLAR (cariprazine) capsule, gelatin coated. — Structured Product Label, confirms labeler and effective date.
  3. Hardy RE, Chung I, Yu Y, Loh SHY, Morone N, Soleilhavoup C, Travaglio M, Serreli R, Panman L, Cain K, Hirst J, Martins LM, MacFarlane M, Pryde KR. The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors. Biology Direct. 2023;18. — PMID 37528429. DOI 10.1186/s13062-023-00375-9. Bovine/mouse isolated mitochondria, human SH-SY5Y cells, primary mouse neurons, Drosophila, drug-specific (cariprazine one of three drugs tested).
  4. Ľupták M, Fišar Z, Hroudová J. Effect of Novel Antipsychotics on Energy Metabolism - In Vitro Study in Pig Brain Mitochondria. Molecular Neurobiology. 2021;58(11):5548-5563. — DOI 10.1007/s12035-021-02498-4. Isolated pig brain mitochondria, in vitro, drug-specific (cariprazine one of four drugs tested: brexpiprazole, cariprazine, loxapine, lurasidone).
  5. Mitrovic M, Simovic Markovic B, Rosic G, Ristic M, Jovicic N, Jurisic V, Milosavljevic J, Matic S, Ljujic B, Selakovic D. Antipsychotic Drug Cariprazine Induces Distinct Cell Death Mechanisms in HeLa and HCT116 Cells as a Potential Inhibitor of Qi-Site of Cytochrome bc1 Reductase. Biomedicines. 2026;14(2):315. — DOI 10.3390/biomedicines14020315. Human cancer cell lines (HeLa, HCT116) plus MRC-5 control, in vitro, drug-specific; exploratory anticancer research, not psychiatric-dosing toxicology.Off-label, off-population (cancer cell lines) context; used only to corroborate the direction of the mitochondrial-complex-inhibition signal, not as primary clinical evidence.
  6. Culpepper L, Vieta E, Kelly DL, Patel MD, Szatmári B, Hankinson A, Earley WR. Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. Neuropsychiatric Disease and Treatment. 2022;18:995-1011. — PMID 35591886. DOI 10.2147/NDT.S348143. Post hoc pooled analysis of randomized, double-blind, placebo- and active-comparator-controlled trials and open-label extensions; over 3,000 patients pooled across schizophrenia and bipolar indications; drug-specific, comparators risperidone and aripiprazole.
  7. Schoretsanitis G, Nikolakopoulou A, Guinart D, Correll CU, Kane JM. Iron homeostasis alterations and risk for akathisia in patients treated with antipsychotics: A systematic review and meta-analysis of cross-sectional studies. European Neuropsychopharmacology. 2020;35:1-11. — DOI 10.1016/j.euroneuro.2020.04.001. Meta-analysis of 10 cross-sectional studies (n=395); included studies (e.g., Brown 1987, Barton 1990, Hofmann 2000, Kuloglu 2003) predate cariprazine's 2015 approval.Cariprazine confirmed absent from the iron-measured cohort; cariprazine's 17.2% akathisia-incidence figure appears only in this paper's background discussion of recent SGA akathisia rates generally, not from the iron-measured studies. Tier C, class extrapolation for the iron-akathisia link specifically.
  8. Antipsychotic-Induced Remodeling of the Gut Microbiota: Drug-Specific Patterns and Molecular Links to Metabolic Adverse Effects. International Journal of Molecular Sciences. 2026;27(19):8471. — Drug-specific review covering olanzapine, risperidone, clozapine, quetiapine, aripiprazole, lurasidone, and amisulpride.Full-text search for "cariprazine" returned no results; cariprazine is not discussed in this review at all. Used as evidence of absence, not as a positive drug-specific source.
  9. Masand PS, McIntyre RS, Cutler AJ, Ganz ML, Lorden AL, Patel K, Kramer K, Harrington A, Nguyen HB. Estimating Changes in Weight and Metabolic Parameters Before and After Treatment With Cariprazine: A Retrospective Study of Electronic Health Records. Clinical Therapeutics. 2024;46(1):50-58. — DOI 10.1016/j.clinthera.2023.10.015. Retrospective EHR cohort (Optum Humedica), n=2,301 primary weight analysis, drug-specific.
  10. Verma A, Ranjan R, Kumar P, Maharshi V. Effect of cariprazine versus aripiprazole on cardiometabolic profile in patients with schizophrenia switched from olanzapine due to weight gain: A randomized controlled trial. Journal of Psychiatric Research. 2026;196:340-348. — DOI 10.1016/j.jpsychires.2026.02.037. Randomized, parallel-arm, 12-week trial, n=98, drug-specific, active comparator aripiprazole (not a placebo/no-treatment comparison; noted per Step 5 limitation).
  11. Cariprazine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf, National Institute of Diabetes and Digestive and Kidney Diseases. — NBK548595. Hepatotoxicity likelihood score E* (unproven but suspected rare cause); mechanism proposed as a toxic metabolic intermediate, unconfirmed.
  12. Optimal Living Dynamics. 7 Important Nutrients Depleted by Psychiatric Drugs. — Tier D consumer content, checked for circulating claims. Names aripiprazole, quetiapine, risperidone, and other antipsychotics in its CoQ10-depletion discussion; cariprazine and Vraylar do not appear anywhere in the article.Consumer content, Tier D; cited only to document the absence of a cariprazine-specific circulating claim, not as supporting evidence.
  13. U.S. Pharmacist. Drug-Induced Nutrient Depletions: What Pharmacists Need to Know. — Tier D consumer/professional content, checked for circulating claims. No mention of cariprazine, Vraylar, or antipsychotics as a class anywhere in the article.Consumer/professional content, Tier D; cited only to document the absence of a cariprazine-specific circulating claim.
  14. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, cariprazine. — Confirms ATC code N05AX15.
  15. PubMed search-listing pages, multiple direct queries. — "cariprazine copper" (0 results), "cariprazine iron ferritin" (0 results), "cariprazine anemia" (0 results, confirmed again on this revision pass), "cariprazine oxidative stress" (3 results, none a human drug-specific biomarker study), "cariprazine hemoglobin" (2 results, both on weight/metabolic parameters, not hematologic), "antipsychotic copper serum schizophrenia" (12 results, reviewed for class-level evidence; see Copper entry). Used to establish and cross-check genuine evidence gaps rather than as positive sources, except where noted below.
  16. Saghazadeh A, Mahmoudi M, Meysamie A, Gharedaghi M, Zamponi GW, Rezaei N. Trace Elements in Schizophrenia: A Systematic Review and Meta-analysis of 39 Studies (N = 5151 Participants). Nutrition Reviews. 2020;78(4):278-303. — DOI 10.1093/nutrit/nuz059. Meta-analysis abstract confirms: "higher levels of copper in plasma, in users of typical antipsychotic drugs, and in males" (quoted directly). Cariprazine is not, and cannot be, in this cohort (approved 2015; most included studies predate it), and the reported copper effect is specific to typical/first-generation antipsychotics, not atypical or D2/D3 partial-agonist drugs.Tier C, class extrapolation from a pharmacologically distant class member (full D2 antagonists). Full text was not accessible: no open-access location via Unpaywall, and the publisher page (academic.oup.com) blocked automated access beyond the abstract.
  17. Herrán A, Vázquez-Barquero JL, González-Hoyos I, et al. Higher levels of serum copper in schizophrenic patients treated with depot neuroleptics. Psychiatry Research. 2000;94(1):51-58. — DOI 10.1016/S0165-1781(00)00126-8. Consistent in direction with the Saghazadeh meta-analysis; concerns depot (typical, first-generation) neuroleptics, not cariprazine or any partial agonist.Only the title and bibliographic record (via Crossref) were accessible this session, not the full abstract; cited as title-confirmed corroborating context, not as an independently verified primary finding. Cariprazine confirmed absent from this cohort (predates cariprazine's 2015 approval by 15 years).
  18. Crossref API queries, this revision pass. — "aripiprazole copper serum" and "antipsychotic copper trace element schizophrenia" (both HTTP 429 before returning); "antipsychotic copper serum schizophrenia" via PubMed instead (12 results, see above); "aripiprazole brexpiprazole hemoglobin anemia" (13 results, no hematologic hit); "antipsychotic hemoglobin anemia schizophrenia" (15 results, no hematologic-outcome hit); "cariprazine hematologic safety laboratory" (15 results, surfaced the Kotlarska et al. 2026 laboratory-monitoring review below). Used to check for D2/D3 partial-agonist-specific or broader antipsychotic-class copper and oxygen-delivery evidence.
  19. Kotlarska KM, Kotlarski W, Mainka T, Sergejuk E. Laboratory Monitoring of Metabolic Safety During Cariprazine Treatment in Schizophrenia and Bipolar Disorder: A Systematic Review. International Journal of Innovative Technologies in Social Science. 2026;2(50). — DOI 10.31435/ijitss.2(50).2026.5550. Drug-specific systematic review of 11 studies on cariprazine's laboratory-monitored metabolic profile (weight, glucose, lipids, prolactin); abstract confirms scope is limited to metabolic parameters, with no copper, iron, or hematologic parameters covered, corroborating the absence of drug-specific literature on those categories rather than providing positive evidence.Publisher page (rspublisher.org) blocked automated full-text access; abstract only, via Crossref metadata.
  20. FDA label full-text term search, this revision pass. — Directly searched the complete VRAYLAR prescribing information (same document as source 1) for "copper," "ceruloplasmin," "anemia," "hemoglobin," "hematocrit," "red blood cell," and "oxygen": none appear anywhere in the label.